In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Impact of metabolic syndrome and obesity on clinical outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

Session Poster session 1

Speaker Seung Hun Lee

Event : ESC Congress 2015

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Coronary Intervention
  • Session type : Poster Session

Authors : SH Lee (Gwangju,KR), MH Jeong (Gwangju,KR), JH Kim (Gwangju,KR), H Park (Gwangju,KR), HK Kim (Gwangju,KR), DS Sim (Gwangju,KR), YJ Hong (Gwangju,KR), Y Ahn (Gwangju,KR), JG Cho (Gwangju,KR), JC Park (Gwangju,KR)

Authors:
S.H. Lee1 , M.H. Jeong1 , J.H. Kim1 , H. Park1 , H.K. Kim1 , D.S. Sim1 , Y.J. Hong1 , Y. Ahn1 , J.G. Cho1 , J.C. Park1 , 1Chonnam National University Hospital, Cardiology - Gwangju - Korea, Republic of ,

Citation:
European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 139

Background: The correlation between obesity and metabolic syndrome (MetS) remains unclear.

Purpose: This study aims to investigate impact of obesity phenotype on clinical outcomes with ST-segment elevation myocardial infarction (STEMI).

Subjects and methods: We analyzed in-hospital mortality and major adverse cardiac events (MACE) of 2,606 obese patients who underwent primary percutaneous coronary intervention (PCI) in the Korea Acute Myocardial Infarction Registry from November 2005 to October 2010. Patients were divided into two groups: unhealthy (any of the Mets components) obesity (BMI ≥25 kg/m2) and healthy (none of the Mets components) obesity.

Results: The unhealthy obesity group was composed of 703 patients (27%) and healthy obesity group 1,903 patients (73%). Unhealthy obesity was more frequent in female (25.9% vs. 10.1%, P<0.001) and multi-vessel disease (53.1% vs. 47.6%, P=0.012). There were no significant differences in other baseline characteristics, angiographic and procedural findings, and prescribed medications between two groups. The overall incidence of complications after PCI (13.1% vs. 10.7%, P=0.097) and in-hospital mortality (1.9% vs. 1.6%, P=0.521) were similar in unhealthy obesity group compared with healthy obesity group. By the multivariate Cox regression analyses, the presence of Mets in obese patients was not an independent factor for predicting the adjusted MACE rate at one-month (HR 1.19, 95% CI 0.56–2.54, P=0.645), six-month (HR 1.48, 95% CI 0.94–2.32, P=0.088), and twelve-month (HR 1.10, 95% CI 0.75–1.61, P=0.622).

Conclusion: Obesity phenotype is not an independent prognostic factor for patients with STEMI who undergoing primary PCI. The risk stratification by presence or absence of Mets is not useful in these patients.

This content is currently on FREE ACCESS, enjoy another 18 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are